The Greek Scientist Combatting the Coronavirus in the U.S.

NEW YORK – Dr. Christos Kyratsous is the Vice President of Research of Infectious Diseases and Viral Vector Technologies at Regeneron Pharmaceuticals, Inc. His name may sound familiar: a few months ago, he and his U.S.-based team made headlines for developing an experimental drug that has been shown to dramatically improve survival rates for the deadly Ebola virus. Today, he is making headlines for a similar and just as important reason: finding a treatment for the newest potential pandemic: the coronavirus.

The Greek scientist, a graduate of Thessaloniki’s Aristotle University with a PhD from Columbia University in New York, spoke to The National Herald about the race against time and the search to find a treatment for the deadly illness.

The National Herald: What is the substance of your agreement with the government regarding the treatment of the coronavirus and what is the timeline for the treatment to be ready?

Christos Kyratsous: Our collaboration with HHS [United States Department of Health and Human Services], originally established in 2017, is focused on discovery, research, development, and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health, now including the Influenza virus and 2019-nCoV. This effort utilizes Regeneron’s proprietary VelociSuite technologies – including the VelocImmune platform which uses a unique genetically-engineered mouse with a humanized immune system that can be challenged with all or parts of a virus of interest – to facilitate swift identification, preclinical validation, and development of promising antibody candidates.  VelociSuite technologies are particularly well-suited for use in quickly-developing outbreak situations, as was done for Ebola.

Generally, we feel well-equipped to tackle the challenge of this novel coronavirus given our turn-key technology for rapid antibody therapeutic development, as well as our track record in infectious diseases, including the similar coronavirus MERS-CoV. Each disease/case is different, but as a reference point, for Ebola it took us six months to discover brand new antibodies, isolate them and demonstrate their efficacy in preclinical models (this is very fast compared to ‘normal’ drug development timelines). If we are able to apply some of our existing antibodies against the novel coronavirus, timelines may be quicker.

TNH: Is the procedure for finding a treatment for this virus analogous to the case of Ebola where you were assigned a similar mission?

CK: Yes, we recently successfully applied our same technology to develop a new treatment for Ebola. We are very proud of the impact REGN-EB3, our investigational treatment, has had in the Democratic Republic of Congo, where it is still being administered to patients in the current outbreak. REGN-EB3 is currently under review by the U.S. Food and Drug Administration.

TNH: Is the coronavirus more threatening than SARS?

CK: It’s hard to make an assessment like that, especially since much is still being learned about the current coronavirus. We know this is a serious outbreak and we are eager to deploy our technologies to hopefully help as many people as possible.

TNH: What is the prognosis of a patient who is infected with the coronavirus? Which patients are most vulnerable? 

CK: I think we are still learning these things about 2019-nCov. The most current information is probably best provided by the WHO [World Health Organization] or other global health organizations who are tracking the outbreak data in real-time.

TNH: How can the spread of the coronavirus be confined or restricted? Do you think the travel ban is a good solution?

CK: Good sense measures in terms of washing hands, staying home when ill, etc. should always be followed regardless of outbreak scenarios. Individual governments and health authorities will have to assess larger responses, and we aren’t in a position to comment on those approaches.




LONDON - Prime Minister Kyriakos Mitsotakis had a meeting with Greeks of the diaspora while in London on Wednesday, during which he highlighted the options that Greeks living abroad now have to vote in Greek elections from their place of residence, as well as his government's emphasis on reforms.

Top Stories


BOSTON – The Holy Synod of the Patriarchate of Alexandria in its recent meeting dealt with the ecclesiastical coup perpetrated by the Patriarchate of Moscow in its canonical jurisdiction, calling it an “immoral invasion and intrusion.


NEW YORK - Some 21 years after it was destroyed in the September 11, 2001 terrorist attacks in the United States that brought down the Twin Towers in New York City, the new St Nicholas Greek Orthodox Church rising in its place is among the most eagerly awaited architectural openings of 2022.


STATEN ISLAND, NY – For yet another year, the community of Holy Trinity-St Nicholas in Staten Island honored couples celebrating 50+ years of marriage with a modest ceremony held at the church immediately following the Divine Liturgy on January 16.


Greece: Heavy Snowfall is Expected on Monday, Schools to Remain Closed in Attica (Vid)

ATHENS - Schools of all levels of education will remain closed throughout Attica on Monday and Tuesday, January 24-25, due to extreme weather conditions.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.